68Ga标记去铁胺-B用于细菌感染显像的临床前评价
该研究对临床已使用的铁载体去铁胺-B(DFO-B)进行68Ga标记,在体外和动物感染模型中评估其作为细菌感染PET显像剂的价值。结果显示[68Ga]Ga-DFO-B放射化学纯度高、稳定性好,在铜绿假单胞菌和金黄色葡萄球菌感染灶中高且特异性聚集,无菌性炎症及缺乏DFO-B转运体的菌株无摄取,估计人体吸收剂量为0.02 mSv/MBq。
要点
- [68Ga]Ga-DFO-B在铜绿假单胞菌和金黄色葡萄球菌感染中高且特异性聚集,图像对比度优良。
- 无菌性炎症、热灭活菌及缺乏DFO-B转运体的大肠杆菌均无摄取,提示摄取具有细菌特异性。
- 估计人体吸收剂量为0.02 mSv/MBq,低于其他68Ga标记放射性药物。
核心结论
- [68Ga]Ga-DFO-B在体外和小鼠体内均被铜绿假单胞菌和金黄色葡萄球菌高且特异性摄取,证明其用于细菌感染特异性显像的潜力。
- DFO-B已在临床使用多年且估计辐射剂量低于其他68Ga标记放射性药物,作者认为其具有较大的临床转化潜力。
研究设计与样本
- 临床前评价研究:对临床使用的铁载体去铁胺-B(Desferal®,DFO-B)进行68Ga标记,开展体外表征、体外微生物摄取实验、健康小鼠体内生物分布与人体剂量估算,以及在动物感染模型中的PET/CT显像。
主要发现
- DFO-B以高放射化学纯度标记68Ga,表现为亲水性、低蛋白结合,在人血清和PBS中稳定性高。
- [68Ga]Ga-DFO-B在选定的铜绿假单胞菌、金黄色葡萄球菌和无乳链球菌菌株中体外摄取高,可被过量铁-DFO-B阻断。
- 健康小鼠中[68Ga]Ga-DFO-B经肾脏快速排泄,血液和其他器官滞留极少。
- 动物感染模型PET/CT显示[68Ga]Ga-DFO-B在铜绿假单胞菌和金黄色葡萄球菌感染中高且特异性聚集,图像对比度优良。
- 无菌性炎症、热灭活的铜绿假单胞菌或金黄色葡萄球菌以及缺乏DFO-B转运体的大肠杆菌中未见摄取。
关键数值与推荐
- 估计人体吸收剂量为0.02 mSv/MBq。
临床怎么用
- 作者基于临床前结果认为[68Ga]Ga-DFO-B有较大临床转化潜力,可用于细菌感染的特异性PET显像,但尚未在患者中验证。
局限性
- 本研究为临床前评价,结论基于体外实验和小鼠模型,尚未报告人体诊断效能数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: With the increase of especially hospital-acquired infections, timely and accurate diagnosis of bacterial infections is crucial for effective patient care. Molecular imaging has the potential for specific and sensitive detection of infections. Siderophores are iron-specific chelators recognized by specific bacterial transporters, representing one of few fundamental differences between bacterial and mammalian cells. Replacing iron by gallium-68 without loss of bioactivity is possible allowing molecular imaging by positron emission tomography (PET). Here, we report on the preclinical evaluation of the clinically used siderophore, desferrioxamine-B (Desferal®, DFO-B), radiolabelled with 68Ga for imaging of bacterial infections. METHODS: In vitro characterization of [68Ga]Ga-DFO-B included partition coefficient, protein binding and stability determination. Specific uptake of [68Ga]Ga-DFO-B was tested in vitro in different microbial cultures. In vivo biodistribution was studied in healthy mice and dosimetric estimation for human setting performed. PET/CT imaging was carried out in animal infection models, representing the most common pathogens. RESULTS: DFO-B was labelled with 68Ga with high radiochemical purity and displayed hydrophilic properties, low protein binding and high stability in human serum and PBS. The high in vitro uptake of [68Ga]Ga-DFO-B in selected strains of Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus agalactiae could be blocked with an excess of iron-DFO-B. [68Ga]Ga-DFO-B showed rapid renal excretion and minimal retention in blood and other organs in healthy mice. Estimated human absorbed dose was 0.02 mSv/MBq. PET/CT images of animal infection models displayed high and specific accumulation of [68Ga]Ga-DFO-B in both P. aeruginosa and S. aureus infections with excellent image contrast. No uptake was found in sterile inflammation, heat-inactivated P. aeruginosa or S. aureus and Escherichia coli lacking DFO-B transporters. CONCLUSION: DFO-B can be easily radiolabelled with 68Ga and displayed suitable in vitro characteristics and excellent pharmacokinetics in mice. The high and specific uptake of [68Ga]Ga-DFO-B by P. aeruginosa and S. aureus was confirmed both in vitro and in vivo, proving the potential of [68Ga]Ga-DFO-B for specific imaging of bacterial infections. As DFO-B is used in clinic for many years and the estimated radiation dose is lower than for other 68Ga-labelled radiopharmaceuticals, we believe that [68Ga]Ga-DFO-B has a great potential for clinical translation.
引用
- Petrik M, Umlaufova E, Raclavsky V, et al. 68Ga-labelled desferrioxamine-B for bacterial infection imaging. Eur J Nucl Med Mol Imaging. 2020. PMID: 32734456. doi:10.1007/s00259-020-04948-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。